DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:29 AM

DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66 Closing the day 09:44 at 13.50 +0.03 +0.22% With a day low of 13.43 and a total volume of 52,446.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.35 (-0.12)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.35 (-0.12)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.35 (-0.12)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.35 (-0.12)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.35 (-0.12)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 319.06 (-1.96), AMAG: 34.76 (-0.17), BIND: 10.05 (+0.07), DYAX: 13.35 (-0.12)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.35 (-0.12)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.35 (-0.12)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.35 (-0.12)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.35 (-0.12)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.35 (-0.12)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.35 (-0.12)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.35 (-0.12)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.40 (+0.20), BXP: 127.35 (+0.55), AMP: 129.99 (-0.29), MRCY: 13.53 (-0.10), BLDP: 2.55 (unch), ESRX: 77.63 (-0.21), AJG: 48.25 (+0.35), NANO: 14.19 (+0.06), CAP: 22.64 (-0.06), EXTR: 3.74 (-0.01), HTA: 12.48 (+0.08), AEC: 19.58 (+0.10), MCK: 204.51 (+1.38), BGFV: 13.30 (-0.08), FB: 74.15 (-0.57), ARI: 16.49 (-0.01), EXP: 85.76 (-1.75), MWA: 9.83 (-0.11), DYAX: 13.35 (-0.12), FARO: 55.60 (-0.90), NFX: 32.42 (-0.69), KONA: 23.02 (+0.01), AZPN: 37.72 (-0.07), GILD: 103.93 (-2.97), HIW: 42.17 (-0.11), PEI: 21.76 (+0.22), GFIG: 4.86 (+0.01), CHRW: 72.91 (+0.05), HURN: 69.39 (-0.86), DLR: 68.60 (+0.20), HLIT: 6.87 (-0.03), AMCC: 6.24 (-0.10), INVN: 14.27 (+0.01), BOOM: 17.07 (-0.21), CINF: 51.55 (+0.28), KIM: 24.85 (+0.25), OI: 25.58 (-0.30), GPRE: 33.16 (-0.45), EPR: 56.84 (+0.25), APC: 89.23 (-2.19), IPHI: 14.36 (-0.17), HTS: 19.08 (-0.02), MAR: 77.82 (+0.52), INAP: 7.98 (-0.02), CRAY: 34.09 (-0.36), FEIC: 82.62 (-0.47), FISV: 70.28 (+0.43), DNB: 124.97 (-0.04), AFG: 60.55 (+0.08), CEB: 74.97 (-0.49), KEYW: 10.91 (-0.07), PLT: 52.08 (-0.31), MAC: 68.93 (+0.33), CHMT: 23.42 (-0.07), AFL: 59.17 (-0.04), CBT: 46.70 (-0.67), EIX: 62.32 (-0.08), EQR: 69.92 (+0.61)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.35 (-0.12)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.58 (+0.37), BCRX: 10.74 (-0.04), NBIX: 19.20 (-0.08), ONTY: 1.73 (+0.01), DYAX: 13.35 (-0.12)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.35 (-0.12)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.35 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith Reports Q3 2026: A Strategic Shift

A. O. Smith Navigates Change in Third Quarter 2026 It's been a gritty third quarter for A. O. Smith, as the company maneuvers through domestic challenges and crafts a strategic future with international tweaks. They've hammered out $941 million in sales but found themselves grappling with net earnings dipping to $126 million, or $0.93 per diluted share, a mere blip from...

BioMarin Strikes Deal for New Fabry Disease Therapy

BioMarin's Latest Moves in Rare Disease Therapies Now here's a plot twist in the biotechnology landscape. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) just did what they do best—snagging rights to a promising enzyme therapy aimed at turning the tide for Fabry disease. In a deal that spoke volumes about their intentions, BioMarin is forking over a cool $70 million upfront...

Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

Broadway.com Instagram Reaches Million Followers Milestone

Broadway.com's Instagram Ascends to Iconic Status There it is, folks—Broadway.com's Instagram just threw down the gauntlet with a clean, million-follower milestone. That's right, a hefty chunk of people now have a front-row seat to Broadway's electric world, straight from their phones. If you're a Broadway buff or just a casual admirer of glitz and glam, these numbers...

LanguageLine AI App Earns Vizient Technology Kudos

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Landstar Faces Legal Storm Post Earnings Miss

Landstar's Earnings Misstep Sends Shockwaves Alright, let's talk about this snafu at Landstar (NASDAQ: LSTR). They were supposed to deliver an earnings sheet that's all roses, but instead, we got a couple of thorns. Analysts were expecting them to strike gold with EPS numbers between $1.62 to $1.67. What we got? A measly $1.42. Not exactly the shiny haul we were led to...

Quanta Services Reports Record Q3 2026 Earnings

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Marvix AI & Unlimited Systems Forge Game-Changing Partnership

Two Forces Colliding in Specialty Care There's a new dynamic duo in town, and they're set to shake up the specialty practice world. Marvix AI, with its cutting-edge clinical documentation AI, and Unlimited Systems, a powerhouse in revenue cycle management, have teamed up in a way that promises to streamline and optimize the specialty practice workflow substantially....

Service Pros Adds Windshield Repair to Lineup

Revving Up the Service Engine Alright, folks, buckle up because Service Pros Auto Glass, our local go-to for windshield replacements, is cranking up their game. They're stepping into the windshield repair arena across Florida and South Carolina, aiming to save you a buck and keep you safe behind the wheel. That's a double win if you ask me. A Closer Look at the Details...

Thunderly Bags Davey Awards for Creative Franchise Videos

Big Wins from Humble Beginnings Ever notice how some small outfits have a knack for punching above their weight? Thunderly, a Dallas-based marketing agency, is a shining example of that. They've just snagged two Silver Awards at the 22nd Annual Davey Awards—and it’s stirring up talk across the sector. Winning a Davey isn’t child's play; it’s about small teams...